Loading...

Member Profile

EMO Biomedicine was founded in 2004. EMO is the first contract research organization (CRO) that focuses on cell-based assay and therapeutic cell-based product in Taiwan. EMO is one of the qualified CRO for pharmaceuticals declared by Ministry of Economic Affairs, Taiwan.

EMO’s Testing Lab is in compliance with ISO/IEC 17025 and accredited by Taiwan Accreditation Foundation (TAF) and TFDA. The accredited testing scope includes cell-based products, biologics, cell culture supernatant, and whole blood.

EMO’s manufacturing facility and quality management systems for therapeutic cell-based product has been inspected by TFDA for the compliance of Good Tissue Practice (GTP) guidance. In December 2019, EMO’s Cell Processing Unit (CPU) received the certificate of manufacturing MSC-based product from TFDA. EMO is able to offer a complete service, including manufacturing and comprehensive testing, for local and oversea clients.


Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2004 EMO Biomedicine Corp. was estabilshed in 2004.
   2007 EMO obtained the Certificate of Accreditation as a “Testing Laboratory” from Taiwan Accreditation Foundation (TAF), in compliance with ISO/IEC 17025:2005.
   2009 EMO obtained the certificate of accreditation as a qualified “Drugs Testing Laboratory” from Taiwan FDA.
   2010 EMO involved in a cell therapy clinical trial and passed the GTP inspection.
   2016 EMO passed the GTP inspection for RegStem® clinical trial.
   2016 EMO Received “Excellent Award of Laboratory Biorisk Management System Implementation” from Centers for Disease Control (CDC), Ministry of Health and Welfare, TAIWAN.
   2019 EMO completed the Phase 1 patient enrollment for RegStem®, a MSCs product, under Taiwan FDA.
   2019 EMO passed the GTP inspection for RegStem® clinical use according to RASMTE.
   2019 EMO’s CPU received GTP-compliant certificate from MOHW, according to RASMTE. It is the first passed autologous adipose stem cells CPU for treatment of degenerative arthritis and knee articular cartilage defects in Taiwan.
   2021 EMO obtained an R.O.C. Invention Patent - USE OF MESENCHYMAL STEM CELLS IN TREATING IMMUNE-RELATED DISEASES, which is EMO independently developed for IDO Quantitative Test to evaluate mesenchymal stem/stromal cells (MSCs) potency.